Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583866 · ClinicalTrials.gov registry record · Early Phase 1
Adiposity and Endothelin Receptor Function
A Early Phase 1 study of Hypertension, sponsored by Augusta University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03583866: Active Early Phase 1 study of Hypertension, sponsored by Augusta University.
NCT03583866 is a Early Phase 1 study of Hypertension that is active but no longer recruiting, run by Augusta University. The registered enrollment target is 25 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03583866, a Early Phase 1 study of Hypertension, is active but no longer recruiting, sponsored by Augusta University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
Primary Outcome
Change in Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and several hours after treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candesartan
Study Locations (1)
Georgia
- Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2026-01 |
| Phase | Early Phase 1 |
What the registry record for NCT03583866 still lists
NCT03583866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03583866 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03583866 about?
NCT03583866 is a clinical study titled "Adiposity and Endothelin Receptor Function". Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor ...
What is the current status of trial NCT03583866?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2018-05-21. Estimated completion is 2026-01.
What conditions does trial NCT03583866 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT03583866?
The interventions under investigation include: Placebo (DRUG), Candesartan (DRUG).
Who is sponsoring clinical trial NCT03583866?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03583866 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03583866's enrollment target sits among peer trials
25 423rd of 470 higher than 43 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
-
Reversing Glucose and Lipid-mediated Vascular Dysfunction
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI